The stock of Repligen Corporation (NASDAQ:RGEN) is a huge mover today! The stock is down 5.09% or $1.33 after the news, hitting $24.8 per share. About 183,190 shares traded hands. Repligen Corporation (NASDAQ:RGEN) has declined 23.86% since August 19, 2015 and is downtrending. It has underperformed by 21.76% the S&P500. The move comes after 7 months negative chart setup for the $846.39 million company. It was reported on Mar, 28 by Barchart.com. We have $23.06 PT which if reached, will make NASDAQ:RGEN worth $59.25 million less.
Out of 4 analysts covering Repligen (NASDAQ:RGEN), 3 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Repligen was the topic in 2 analyst reports since November 6, 2015 according to StockzIntelligence Inc.
According to Zacks Investment Research, “Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS? series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development.”
The institutional sentiment increased to 1.43 in 2015 Q3. Its up 0.62, from 0.81 in 2015Q2. The ratio increased, as 18 funds sold all Repligen Corporation shares owned while 57 reduced positions. 23 funds bought stakes while 84 increased positions. They now own 28.32 million shares or 6.62% less from 30.32 million shares in 2015Q2.
Tamro Capital Partners Llc holds 1.81% of its portfolio in Repligen Corporation for 572,069 shares. Conestoga Capital Advisors Llc owns 664,775 shares or 1.48% of their US portfolio. Moreover, Awm Investment Company Inc. has 1.02% invested in the company for 190,000 shares. The Minnesota-based Arbor Capital Management Llc has invested 0.76% in the stock. D L Carlson Investment Group Inc, a New Hampshire-based fund reported 50,090 shares.
Repligen Corporation - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.